Search

Denibulin

Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

Hydrocortisone aceponate

Tubercidin

An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

Romlusevimab

Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

Ditiocarb zinc

Sensitivity to ditiocarb zinc may be identified with a clinical patch test.

Virus Specific T-Cell

Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. … These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs.

Pexelizumab

It is being investigated by Alexion Pharmaceuticals.

Aluminum zirconium pentachlorohydrex gly

Its anhydrous form allows the molecule to absorb moisture.

1D09C3

class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC

Melanoma antigen recognized by T-cells 1

Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery